AUPH
Aurinia Pharmaceuticals Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 26 ▲ Aurinia Pharmaceuticals reported strong financial results for 2025,…
- Feb 27 to Mar 3 ▲ 3 days of insider buys: $12.7M by 1 insider, avg $14.10
- May 29 to Jun 2 ▲ 3 days of insider buys: $12.5M by 1 insider, avg $15.29
- Jun 3 ▲ Aurinia CEO Kevin Tang made a conviction buy of ~552K shares (~$8.4M…
- Aug 6 ▲ Aurinia Pharmaceuticals reported Q2 2026 revenue of $83.2M (+19% YoY…
- Aug 21 ▼ 1 insider sell $355.9K at $16.97
- Sep 10 ▼ 1 insider sell $190.4K at $15.95
- Oct 30 ▲ Earnings: AUPH Q3 2026 Earnings: EPS $0.23 (+2.5% vs est)
Signal stack
Where each data set points today.
- InsidersBULLISH
1 insider bought $25.1M at an average $14.66. 1 insider sold $546.4K. Price is 6% above their cost.
- InstitutionsBULLISH
Q3 2026: 29 added (0 new), 18 trimmed or exited.
- AnalystsBULLISH
9 of 12 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate $0.226 → $0.214 over 90 days. 2 up, 2 down in 30 days.
- Short sellersSTEADY
Short interest −8.3% to 7.14M shares. 10.3 days to cover, ≈5.3% of shares.
- TrendDOWNTREND
6% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| Nuveen, LLC | ADD | $20.2M |
| Qube Research & Technologies Ltd | DOUBLED | $16.0M |
| FMR LLC | ADD | $8.4M |
| FEDERATED HERMES, INC. | DOUBLED | $7.6M |
| CAPITAL FUND MANAGEMENT S.A. | DOUBLED | $5.3M |
| PRINCIPAL FINANCIAL GROUP INC | ADD | $4.1M |
| FRANKLIN TEMPLETON INC | ADD | $3.5M |
| Connor, Clark & Lunn Investment Management Ltd. | TRIM | $3.4M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
12 analystsPrice is below the lowest target. Median implies +16%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 2, 2026 | RBC Capital MAINTAIN | Sector Perform |
| Oct 21, 2026 | TD Cowen MAINTAIN | Buy |
| Aug 7, 2026 | RBC Capital MAINTAIN | Sector Perform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Robertson Stephen P. Chief Legal Officer Sep 10, 2026 | SELL | $190.4K |
Robertson Stephen P. Chief Legal Officer Aug 21, 2026 | SELL | $355.9K |
Johnson Craig A Director Jun 4, 2026 | AWARD | 23,931 sh |
Nova Tina Susan Director Jun 4, 2026 | AWARD | 23,931 sh |
Bailey Jeffrey Allen Director Jun 4, 2026 | AWARD | 23,931 sh |
Goetz Kathleen Director Jun 4, 2026 | AWARD | 23,931 sh |
TANG KEVIN Chief Executive Officer Jun 2, 2026 | OTHER | $16.5K |
TANG KEVIN Chief Executive Officer Jun 2, 2026 | BUY | $3.1M |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $0.21 | $0.17–$0.24 | +7.0% | $85.5M |
| Next Q | $0.19 | $0.17–$0.21 | +11.8% | $83.0M |
| Current FY | $0.97 | $0.93–$1.00 | +2.8% | $330.1M |
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
7 filings · 3 bullish · 0 bearish · 1 mixed · 3 neutral- MIXED INST-CLUSTERNov 16, 2026
Institutional activity in AUPH during Q2 2026 was mixed: 19 buyers accumulated $81.9M in new positions, led by Goldman Sachs doubling its stake (+$74.1M), while 16 sellers reduced holdings by $24.9M, with notable near-exits from Jane Street Group, Walleye Capital, and BNP Paribas. The cluster is…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL INST-CLUSTERNov 2, 2026
Three institutional asset managers added to their AUPH positions in Q3 2026, increasing aggregate…
The institutional buying is modest in scale ($2.2M net) and comes from asset managers rather than activist or event-driven funds, suggesting a thesis of steady commercial execution rather than a…
- NEUTRAL 8-KOct 30, 2026
Aurinia Pharmaceuticals reported Q3 2026 total revenue of $83.7M (+14% YoY) and GAAP diluted EPS…
Results were in line with expectations, but the modest guidance raise and flat EPS YoY provide limited upside catalyst. The activist stake (ILJIN, filed Aug 27) adds pressure for operational…
- BULLISH 8-KAug 6, 2026
Aurinia Pharmaceuticals reported Q2 2026 revenue of $83.2M (+19% YoY) and diluted EPS of $0.28…
The strong beat on both revenue and EPS, combined with maintained guidance and a growing pipeline, supports a bullish outlook. Traders should watch for continued LUPKYNIS adoption and any updates…
All AUPH filing & press-release reports (7)
- INST-CLUSTER reportNov 16, 2026
- INST-CLUSTER reportNov 2, 2026
- 8-K reportOct 30, 2026
- 8-K reportAug 6, 2026
- INSIDER-BUY reportJun 2, 2026
- 8-K reportMay 11, 2026
- 8-K reportFeb 26, 2026